INTRODUCTION: Salivary lysozyme (SLZ) is a proteolytic enzyme secreted by oral leucocytes and contains a domain that has an affinity to advanced glycation end products (AGE). Thus, we hypothesized that SLZ would be associated with metabolic syndrome (metS), a pro-inflammatory state. METHODS: Utilizing cross-sectional data from 250 coronary artery disease (CAD) and 250 non-CAD patients, the association of SLZ with metS was tested by logistic regression analyses controlling for age, sex, smoking, total cholesterol and C-reactive protein (CRP) levels. The analyses were stratified by CAD status to control for the possible effects of CAD. RESULTS: MetS was found in 122 persons. The adjusted odds ratio (OR) for metS associated with the highest quartile of SLZ was 1.95 with 95% confidence interval (CI) 1.20-3.12, p-value=0.007, compared with the lower three quartiles combined. Among the 40 subjects with metS but without CAD, the OR was 1.63 (CI: 0.64-4.15, p=0.31), whereas in the CAD group, SLZ was significantly associated with metS [OR=1.96 (1.09-3.52), p=0.02]. In both subgroups, CRP was not significantly associated with metS. CONCLUSION: SLZ was significantly associated with metS (OR=1.95) independent of CRP level. Future longitudinal research is warranted.
INTRODUCTION: Salivary lysozyme (SLZ) is a proteolytic enzyme secreted by oral leucocytes and contains a domain that has an affinity to advanced glycation end products (AGE). Thus, we hypothesized that SLZ would be associated with metabolic syndrome (metS), a pro-inflammatory state. METHODS: Utilizing cross-sectional data from 250 coronary artery disease (CAD) and 250 non-CAD patients, the association of SLZ with metS was tested by logistic regression analyses controlling for age, sex, smoking, total cholesterol and C-reactive protein (CRP) levels. The analyses were stratified by CAD status to control for the possible effects of CAD. RESULTS: MetS was found in 122 persons. The adjusted odds ratio (OR) for metS associated with the highest quartile of SLZ was 1.95 with 95% confidence interval (CI) 1.20-3.12, p-value=0.007, compared with the lower three quartiles combined. Among the 40 subjects with metS but without CAD, the OR was 1.63 (CI: 0.64-4.15, p=0.31), whereas in the CAD group, SLZ was significantly associated with metS [OR=1.96 (1.09-3.52), p=0.02]. In both subgroups, CRP was not significantly associated with metS. CONCLUSION: SLZ was significantly associated with metS (OR=1.95) independent of CRP level. Future longitudinal research is warranted.
Authors: Simin Liu; Mary Serdula; Sok-Ja Janket; Nancy R Cook; Howard D Sesso; Walter C Willett; Joann E Manson; Julie E Buring Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: M Karima; A Kantarci; T Ohira; H Hasturk; V L Jones; B-H Nam; A Malabanan; P C Trackman; J A Badwey; T E Van Dyke Journal: J Leukoc Biol Date: 2005-08-04 Impact factor: 4.962
Authors: Vahitha B Abdul-Salam; Punit Ramrakha; Unni Krishnan; David R Owen; Joseph Shalhoub; Alun H Davies; Tjun Y Tang; Jonathan H Gillard; Joseph J Boyle; Martin R Wilkins; Robert J Edwards Journal: Arterioscler Thromb Vasc Biol Date: 2010-02-18 Impact factor: 8.311
Authors: Sok-Ja Janket; Alison E Baird; Judith A Jones; Elizabeth A Jackson; Markku Surakka; Wen Tao; Jukka H Meurman; Thomas E Van Dyke Journal: J Clin Periodontol Date: 2013-12-10 Impact factor: 8.728
Authors: Nilminie Rathnayake; Sigvard Akerman; Björn Klinge; Nina Lundegren; Henrik Jansson; Ylva Tryselius; Timo Sorsa; Anders Gustafsson Journal: PLoS One Date: 2013-04-24 Impact factor: 3.240